Effects of pregabalin on sleep in generalized anxiety disorder

Holsboer‐Trachsler, Edith; Prieto, Rita

doi:10.1017/s1461145712000922

Cited by 47 publications

(35 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therapeutic effects of gabapentin and pregabalin on sleep disturbance have also been reported in studies of patients with pain, restless legs syndrome, generalized anxiety disorder, and epilepsy.…”

Section: Management Of Insomniamentioning

confidence: 85%

The assessment and management of insomnia: an update

2019

View full text Add to dashboard Cite

Insomnia poses significant challenges to public health. It is a common condition associated with marked impairment in function and quality of life, psychiatric and physical morbidity, and accidents. As such, it is important that effective treatment is provided in clinical practice. To this end, this paper reviews critical aspects of the assessment of insomnia and the available treatment options. These options include both non-medication treatments, most notably cognitive behavioral therapy for insomnia, and a variety of pharmacologic therapies such as benzodiazepines, "z-drugs", melatonin receptor agonists, selective histamine H1 antagonists, orexin antagonists, antidepressants, antipsychotics, anticonvulsants, and non-selective antihistamines. A review of the available research indicates that rigorous double-blind, randomized, controlled trials are lacking for some of the most commonly administered insomnia therapies. However, there are an array of interventions which have been demonstrated to have therapeutic effects in insomnia in trials with the above features, and whose risk/benefit profiles have been well characterized. These interventions can form the basis for systematic, evidence-based treatment of insomnia in clinical practice. We review this evidence base and highlight areas where more studies are needed, with the aim of providing a resource for improving the clinical management of the many patients with insomnia.

show abstract

Section: Management Of Insomniamentioning

confidence: 85%

The assessment and management of insomnia: an update

2019

View full text Add to dashboard Cite

show abstract

“…Treatment with pregabalin was associated with significant improvement in sleep, including complete remission of insomnia symptoms in at least 40% of patients (Holsboer-Trachsler and Prieto, 2013;Montgomery et al, 2008).…”

Section: Clinical Considerations: Pregabalin and Time-to-responsementioning

confidence: 96%

Efficacy and safety of pregabalin in generalised anxiety disorder: A critical review of the literature

et al. 2015

View full text Add to dashboard Cite

The aim of this review is to summarise the literature on the efficacy and safety of pregabalin for the treatment of generalised anxiety disorder (GAD). Of 241 literature citations, 13 clinical trials were identified that were specifically designed to evaluate the efficacy and safety of pregabalin in GAD, including 11 randomised double-blind trials and two open-label studies. Pregabalin efficacy has been consistently demonstrated across the licensed dose range of 150-600 mg/day. Efficacy has been reported for pregabalin monotherapy in elderly patients with GAD, patients with severe anxiety, and for adjunctive therapy when added to a selective serotonin reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor in patients who have failed to respond to an initial course of antidepressant therapy. The two most common adverse events with pregabalin are somnolence and dizziness, both of which appear to be dose-related. Pregabalin appears to have a low potential for causing withdrawal symptoms when long-term therapy is discontinued; however, tapering over the course of at least one week is recommended. A review of available evidence indicates that pregabalin is a well-tolerated and consistently effective treatment for GAD, with a unique mechanism of action that makes it a useful addition to the therapeutic armamentarium.

show abstract

“…Pregabalin and/or gabapentin are two AEDs that have been shown to improve disturbed sleep in a variety of common conditions, including neuropathic pain [62][63][64], postherpetic neuralgia [65,66], fibromyalgia [67,68], restless legs syndrome [69], general anxiety disorder [70], sleep bruxism [71], menopausal women with insomnia with or without hot flashes [72][73][74][75], and autistic children with refractory insomnia [76]. The evidence suggests that the positive effects of pregabalin are distinct from its analgesic, anxiolytic, and anticonvulsant effects [77].…”

Section: Effects Of Antiepileptic Medications On Sleep and Wakefulnessmentioning

confidence: 99%